Britecyte - About the company
Britecyte is an unfunded company based in Frederick (United States), founded in 2022 by Peter Friedli and Alla Danilkovitch. It operates as a Developer of regenerative medicine therapies using biocompatible cells and tissues. Britecyte has not raised any funding yet. The company has 234 active competitors, including 63 funded and 64 that have exited. Its top competitors include companies like argenx, Vor Biopharma and Nimbus Therapeutics.
Company Details
Developer of regenerative medicine therapies using biocompatible cells and tissues. The company focuses on biologic therapies and tissue allografts for various medical indications. A key program involves a biologic therapy for non-alcoholic steatohepatitis (NASH), targeting metabolic pathways in NASH and adipose tissue. Additionally, it develops innovative regenerative medicine products for soft tissue repair, aiming for rapid market entry.
Key Metrics
Founded Year
2022
Location
Frederick, United States
Stage
Unfunded
Ranked
126th among 234 active competitors
Employee Count
10 as on Aug 31, 2026
Legal entities associated with Britecyte
Britecyte is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
BRITECYTE INC CIN: 881109927 , United States, Active | Dec 31, 1999 | - | 5 (As on Dec 31, 2024) | - |
Sign up to download Britecyte's company profile
Britecyte's funding and investors
Britecyte has not raised any funding rounds yet.
Britecyte's founders and board of directors
Founder? Claim ProfileThe founders of Britecyte are Peter Friedli and Alla Danilkovitch.
Here are the details of Britecyte's key team members:
- Peter Friedli: Co-Founder & Chairman of Britecyte.
- Alla Danilkovitch: Co-Founder of Britecyte.
View details of Britecyte's Founder profiles and Board Members
Britecyte's employee count trend
Britecyte has 10 employees as of Aug 26. Here is Britecyte's employee count trend over the years:
Uncover Britecyte's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Britecyte's Competitors and alternates
Top competitors of Britecyte include argenx, Vor Biopharma and Nimbus Therapeutics. Here is the list of Top 10 competitors of Britecyte, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 75/100 | ||
2nd |  Vor Biopharma 2019, Cambridge (United States), Public | Developer of therapeutics to treat acute myeloid leukemia | $152M | 69/100 | |
3rd |  Nimbus Therapeutics 2009, Cambridge (United States), Series F | Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases | $637M | 65/100 | |
4th |  Mammoth 2017, Brisbane (United States), Series D | Provider of molecular diagnostics platform by using CRISPR technology | $271M | 64/100 | |
5th | Developer of a novel treatment for metabolic diseases | $138M | 64/100 | ||
6th | Radius Health 2003, Boston (United States), Acquired | Biopharmaceutical company focused on bone health and related therapeutic areas | $213M | 62/100 | |
7th |  Aligos Therapeutics 2018, San Francisco (United States), Public | Developer of therapies to treat hepatologic diseases and viral infections | $225M | 62/100 | |
8th | Madrigal Pharmaceuticals 2011, Conshohocken (United States), Acquired | Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis | $38.4M | 62/100 | |
9th | Enyo Pharma 2014, Lyon (France), Series C | Developer of therapeutics for diseases with impaired kidney function | $120M | 62/100 | |
10th |  Mirum Pharmaceuticals 2018, Menlo Park (United States), Public | Developer of small molecule based therapeutics to treat rare diseases | $120M | 61/100 | |
126th | Britecyte 2022, Frederick (United States), Unfunded | Developer of regenerative medicine therapies using biocompatible cells and tissues | - | - | 30/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Britecyte's competitors? Click here to see the top ones
Britecyte's Investments and acquisitions
Britecyte has made no investments or acquisitions yet.
Reports related to Britecyte
Here is the latest report on Britecyte's sector:
News related to Britecyte
Media has covered Britecyte for 1 event in last 1 year, It was about partnerships.
•
$1M Grant from the Maryland Stem Cell Research Fund (MSCRF) Powers Novel Adipose Tissue Allograft Therapy for OsteoarthritisBusiness Wire•Nov 04, 2025•Britecyte, Aramex
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Britecyte
Explore our recently published companies
- Limited Labs AI - Tirana based, Unfunded company
- LikeThat AI - Unfunded company
- Like a Model AI - Belgium based, Unfunded company
- Liidi AI - Unfunded company
- LightVela AI - Unfunded company
- Lightsky AI - Unfunded company
